Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Posted by Scott Moore on Feb 8th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $11.62, for a total value of $23,240.00. Following the completion of the sale, the president now directly owns 2,885,138 shares in the company, valued at approximately $33,525,303.56. This represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total value of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total transaction of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total transaction of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total transaction of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total value of $24,800.00.

Gyre Therapeutics Trading Down 5.1 %

NASDAQ:GYRE opened at $12.10 on Friday. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $26.37. The firm’s 50 day simple moving average is $11.12 and its 200 day simple moving average is $12.43.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently modified their holdings of GYRE. Renaissance Technologies LLC bought a new position in Gyre Therapeutics during the 2nd quarter worth $166,000. Charles Schwab Investment Management Inc. increased its stake in shares of Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the period. Advantage Alpha Capital Partners LP bought a new position in shares of Gyre Therapeutics during the third quarter worth about $334,000. FMR LLC acquired a new position in shares of Gyre Therapeutics in the third quarter worth approximately $47,000. Finally, State Street Corp lifted its stake in shares of Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after acquiring an additional 8,412 shares during the period. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.